Inventera Inc.
KKRX:0007J08,750.00
KRW
-440.00
(-4.79%)
ISIN
KR70007J0006
Return %
Stock
S&P 500
1Y
- -
13.14
3Y
- -
80.78
5Y
- -
67.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seoul South Korea
- IPO Date
- Apr 2, 2026
- Website
- inventera.kr
- Similar Companies
- Business
- Inventera Inc. is a South Korea-based clinical-stage biotechnology company that develops next-generation, nanoparticle-based magnetic resonance imaging (MRI) contrast agents and diagnostic nanomedicines. The company utilizes its proprietary Invinity platform technology to engineer biocompatible, iron-based T1-weighted MRI contrast agents designed to overcome the safety and diagnostic limitations associated with conventional gadolinium-based imaging agents. Inventera Inc. operates across specialized diagnostic imaging segments, offering a pipeline of disease-specific contrast agents, including: INV-002 (NEMO-103), a first-in-class iron-based magnetic resonance arthrography (MRA) contrast agent engineered for high-resolution imaging and diagnosis of musculoskeletal disorders, such as cartilage defects and joint labrum tears; INV-001, an ultra-small nanoparticle contrast agent developed for high-resolution lymphovascular imaging to diagnose lymphatic disorders, including lymphedema; and INV-003, a targeted imaging candidate designed for pancreaticobiliary and hepatobiliary duct diagnostics. The company primarily targets hospitals, diagnostic imaging centers, and healthcare institutions across South Korea, North America, and international markets. In recent operational developments, Inventera Inc. completed its initial public offering and listed on the KOSDAQ market under the ticker symbol 0007J0 in April 2026; successfully completed Phase 3 clinical trials in South Korea for its lead MRA contrast agent candidate INV-002 after achieving all primary safety and efficacy endpoints, advancing the asset toward regulatory marketing approval with the Ministry of Food and Drug Safety; secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to advance Phase 2 clinical trials for INV-001 and Phase 2b clinical trials for INV-002; entered into a strategic licensing and exclusive distribution partnership with Dongkook Life Science for domestic and global commercial distribution; and executed a commercial active pharmaceutical ingredient (API) manufacturing agreement with LG Chem to scale up commercial-grade production for its nanomedicine pipeline. Founded in November 2018, Inventera Inc. is headquartered in Seoul, South Korea.